There are also the side effects like nausea, vomiting and constipation associated with the buildup of food and waste in the digestive tract
In addition, the evidence that oral semaglutide can significantly improve not only glycaemic control and body weight but also cardiovascular risk factors (including blood pressure, lipids and inflammation), supports a cardioprotective action [6]
Merck Partners with Hansoh Pharma on Oral GLP-1 Receptor Agonist for Type 2 Diabetes Merck has entered into an exclusive global license agreement with Hansoh Pharma to develop and commercialize HS-10270, an investigational oral GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity
It is difficult to draw conclusions from the two studies, as their design and interventions differed
You may also be interested in Other personalized therapies our patients explore alongside GLP-1 to support energy, vitality, and overall wellness